Condition (MeSH)
Camurati-Engelmann Syndrome
ClinicalTrials.gov lists 58 trials for Camurati-Engelmann Syndrome or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
58 of the 58 trials are tagged with Camurati-Engelmann Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Camurati-Engelmann Syndrome trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 5 |
| 2024 | 3 |
| 2023 | 2 |
| 2022 | 5 |
| 2021 | 3 |
| 2020 | 4 |
| 2019 | 4 |
| 2018 | 1 |
| 2017 | 1 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Camurati-Engelmann Syndrome trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 11 |
| Phase 1/2 | 4 |
| Phase 2 | 12 |
| Phase 2/3 | 2 |
| Phase 3 | 3 |
| Phase 4 | 2 |
| Not applicable | 11 |
| Observational | 13 |
How many Camurati-Engelmann Syndrome trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 8 |
| Active, not recruiting | 5 |
| Completed | 27 |
| Terminated | 9 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Camurati-Engelmann Syndrome trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| EMD Serono Research & Development Institute, Inc. | 3 |
| Eli Lilly and Company | 3 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 3 |
| Bicara Therapeutics | 2 |
| National Cancer Institute (NCI) | 2 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Camurati-Engelmann Syndrome? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| PEMBROLIZUMAB | 3 |
| LY3200882 | 2 |
| Ficerafusp alfa | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Bintrafusp alfa/M7824 | 5 |
| Cisplatin 1 | 3 |
| Gemcitabine/Gemzar | 2 |
| Low dose losartan | 2 |
| Triamcinolone Acetonide alone | 2 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Camurati-Engelmann Syndrome trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Disease progression | 22 | 4 |
| Cholangitis | 20 | 3 |
| Anaemia | 19 | 5 |
| Pyrexia | 15 | 5 |
| Biliary tract infection | 12 | 3 |
Showing 5 of 10 adverse events.
Prevalence (4)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Camurati-Engelmann disease | Cases families | Worldwide | Not stated | Exact | |
| Camurati-Engelmann disease | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Camurati-Engelmann disease | Cases families | Worldwide | Not stated | Exact | |
| Camurati-Engelmann disease | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Camurati-Engelmann disease | 1328 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Camurati-Engelmann disease | 1328 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: publications and sub-conditions in mesh.